Eteplirsen Notes from the MDA Conference
This afternoon Sarepta presented data on their trial for their lead candidates to skip exon 51 in Duchenne muscular dystrophy at the MDA Conference in Washington DC. Most of this has been presented recently, there are a few more weeks of data here.
Dr. Jerry Mendell presented the 74 week data for eteplirsen:
Eteplirsen continues to demonstrate positive results at 74 weeks. The 6 minute walk test showed an improvement in 65 meters over delayed treatment group .Eteplirsen continues to show acceptable safety profile with no related adverse events through 74 weeks.
Eteplirsen met both it’s primary endpoints at 74 weeks, there were no treatment interruptions.